Medical technology company AngioDynamics, Inc. (NASDAQ: ANGO) on Tuesday reported an increase in net sales for the second quarter of fiscal 2026.
In Q2, net sales increased 8.8% year-over-year to $79.4 million; Med Tech sales grew 13% to $35.7 millionAt $43.8 million, Med Device sales were up 5.6% in Q2, compared to $41.3 million in the prior-year periodAngioDynamics incurred a net loss of $6.4 million or $0.15 per share in Q2, vs. a loss of $10.7 million or $0.26 per share last yearExcluding special items, on an adjusted basis, the company reported break-even for the quarter, compared to a loss of $0.04 per share in Q2 2025Adjusted EBITDA, excluding one-off items, was $5.9 million, compared to $3.1 million in the second quarter of 2025The management said it continues to expect to be cash flow positive in the full fiscal year 2026The company raised its FY26 net sales guidance to $312-314 million from the earlier outlook of $308-313 millionIt expects a loss per share in the range of $0.33-0.23 for FY26, on an adjusted basis, which is unchanged from the prior guidance
-1024x683.jpg "Soft Words, Big Sticks, and an Endgame in Iran")
